8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Feb 18, 2026·SEC
Bausch Health Companies Inc.(BHC)Earnings, Financials & Key Ratios
BHC•NYSE
11.1× P/E·Price updated Jun 19, 2026
AboutBausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Show more
- Revenue$10.45B+8.5%
- EBITDA$3.45B+22.7%
- Net Income$160M+447.3%
- EPS (Diluted)0.43+430.8%
- Gross Margin60.9%-14.3%
- EBITDA Margin33.05%+13.1%
- Operating Margin21.28%+32.5%
- Net Margin1.53%+420.0%
- ROE588.24%
BHC Key Insights
Bausch Health Companies Inc. (BHC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗High debt to equity ratio of 56.4x
- ✗Weak momentum: RS Rating 20 (bottom 20%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BHC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BHC Price & Volume
Bausch Health Companies Inc. (BHC) stock price & volume — 10-year historical chart
Loading chart...
BHC Growth Metrics
Bausch Health Companies Inc. (BHC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years0%
5 Years5.41%
3 Years8.74%
TTM8.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2886.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2758.41%
Return on Capital
10 Years1.82%
5 Years5.18%
3 Years7.38%
Last Year10.61%
BHC Recent Earnings
Bausch Health Companies Inc. (BHC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$0.78-3.7%
$0.81
Rev
$2.5B+4.3%
$2.4B
Q1 2026
Feb 18, 2026Metric
Actual
Est
EPS
$1.08-10.7%
$1.21
Rev
$2.8B+2.1%
$2.7B
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$1.16+8.4%
$1.07
Rev
$2.7B-1.0%
$2.7B
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.90-7.2%
$0.97
Rev
$2.5B-2.1%
$2.6B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.78vs $0.81-3.7% | $2.5Bvs $2.4B+4.3% |
| Q1 2026 | Feb 18, 2026 | $1.08vs $1.21-10.7% | $2.8Bvs $2.7B+2.1% |
| Q4 2025 | Oct 29, 2025 | $1.16vs $1.07+8.4% | $2.7Bvs $2.7B-1.0% |
| Q3 2025 | Jul 30, 2025 | $0.90vs $0.97-7.2% | $2.5Bvs $2.6B-2.1% |
Based on last 12 quarters of dataView full earnings history →
BHC Peer Comparison
Bausch Health Companies Inc. (BHC) competitors in Specialty pharma brand consolidators — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PBH | 2.23B | 46.97 | 12.01 | -4.31% | 17.48% | 10.29% | 0.55 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 BLCO | 5.3B | 14.87 | -14.58 | 6.47% | -4.21% | -3.37% | 0.82 | |
 COO | 12.85B | 65.91 | 35.25 | 5.06% | 5.57% | 2.84% | 0.34 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 ALCO | 299.17M | 40.34 | -2.09 | -5.52% | -115.6% | -17.4% | 0.79 | |
 NVS | 280.64B | 147.08 | 20.46 | 5.97% | 24.14% | 31.42% | 0.80 | |
 EW | 50.37B | 87.36 | 47.74 | 11.55% | 17.64% | 10.35% | 0.07 |
Compare BHC vs Peers
Bausch Health Companies Inc. (BHC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BHC Income Statement
Bausch Health Companies Inc. (BHC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 8.72B | 8.38B | 8.6B | 8.03B | 8.43B | 8.12B | 8.76B | 9.63B | 10.45B | 10.55B |
Revenue Growth % | -9.82% | -3.94% | 2.64% | -6.67% | 5.07% | -3.68% | 7.79% | 9.91% | 8.53% | 8.52% |
Cost of Goods Sold | 2.55B | 2.35B | 2.35B | 2.25B | 2.39B | 2.36B | 2.56B | 2.78B | 4.08B | 4.04B |
COGS % of Revenue | 29.21% | 28.05% | 27.32% | 28.02% | 28.39% | 29.1% | 29.22% | 28.9% | 39.1% | - |
Gross Profit | 6.18B▲ 0% | 6.03B▼ 2.4% | 6.25B▲ 3.7% | 5.78B▼ 7.6% | 6.04B▲ 4.5% | 5.76B▼ 4.6% | 6.2B▲ 7.6% | 6.84B▲ 10.4% | 6.36B▼ 7.0% | 6.51B▲ 0% |
Gross Margin % | 70.79% | 71.95% | 72.68% | 71.98% | 71.61% | 70.9% | 70.78% | 71.1% | 60.9% | 61.67% |
Gross Profit Growth % | -13.03% | -2.38% | 3.68% | -7.57% | 4.53% | -4.64% | 7.6% | 10.41% | -7.04% | - |
Operating Expenses | 6.07B | 8.41B | 6.45B | 5.1B | 5.59B | 5.31B | 5.24B | 5.3B | 4.14B | 4.09B |
OpEx % of Revenue | 69.62% | 100.39% | 75.04% | 63.56% | 66.28% | 65.31% | 59.78% | 55.03% | 39.62% | - |
Selling, General & Admin | 2.58B | 2.47B | 2.55B | 2.37B | 2.49B | 2.53B | 2.9B | 3.28B | 3.5B | 3.44B |
SG&A % of Revenue | 29.6% | 29.51% | 29.69% | 29.49% | 29.55% | 31.15% | 33.06% | 34.11% | 33.49% | - |
Research & Development | 369M | 442M | 516M | 485M | 473M | 530M | 604M | 634M | 640.01M | 650.07M |
R&D % of Revenue | 4.23% | 5.27% | 6% | 6.04% | 5.61% | 6.52% | 6.9% | 6.59% | 6.13% | - |
Other Operating Expenses | 3.12B | 5.5B | 3.38B | 2.25B | 2.63B | 2.25B | 1.74B | 1.38B | 1 | 3 |
Operating Income | 102M▲ 0% | -2.38B▼ 2437.3% | -203M▲ 91.5% | 676M▲ 433.0% | 450M▼ 33.4% | 454M▲ 0.9% | 963M▲ 112.1% | 1.55B▲ 60.5% | 2.22B▲ 43.8% | 2.42B▲ 0% |
Operating Margin % | 1.17% | -28.45% | -2.36% | 8.42% | 5.34% | 5.59% | 11% | 16.06% | 21.28% | 22.91% |
Operating Income Growth % | 118.02% | -2437.25% | 91.48% | 433% | -33.43% | 0.89% | 112.11% | 60.54% | 43.81% | - |
EBITDA | 2.96B | 435M | 1.87B | 2.5B | 2B | 1.85B | 2.23B | 2.81B | 3.45B | 3.62B |
EBITDA Margin % | 33.93% | 5.19% | 21.76% | 31.16% | 23.74% | 22.75% | 25.43% | 29.23% | 33.05% | 34.28% |
EBITDA Growth % | 28.7% | -85.3% | 330.34% | 33.6% | -19.95% | -7.69% | 20.51% | 26.31% | 22.73% | 28.88% |
D&A (Non-Cash Add-back) | 2.86B | 2.82B | 2.08B | 1.82B | 1.55B | 1.39B | 1.26B | 1.27B | 1.23B | 1.2B |
EBIT | 555M | 500M | 1.34B | 1.31B | 1.71B | 1.48B | 1.62B | 1.87B | 2.22B | 2.42B |
Net Interest Income | -1.83B | -1.67B | -1.6B | -1.52B | -1.42B | -1.45B | -1.3B | -1.35B | -1.59B | -1.64B |
Interest Income | 12M | 11M | 12M | 13M | 7M | 14M | 26M | 33M | 48.84M | 47.05M |
Interest Expense | 1.84B | 1.69B | 1.61B | 1.53B | 1.43B | 1.46B | 1.33B | 1.39B | 1.64B | 1.69B |
Other Income/Expense | -1.84B | -1.77B | -1.63B | -1.61B | -1.47B | -583M | -1.35B | -1.38B | -1.85B | -3.34B |
Pretax Income | -1.74B▲ 0% | -4.15B▼ 138.6% | -1.84B▲ 55.8% | -934M▲ 49.2% | -1.02B▼ 9.6% | -129M▲ 87.4% | -390M▼ 202.3% | 167M▲ 142.8% | 373.42M▲ 123.6% | -920.44M▲ 0% |
Pretax Margin % | -19.96% | -49.57% | -21.36% | -11.64% | -12.14% | -1.59% | -4.45% | 1.74% | 3.57% | -8.72% |
Income Tax | -4.14B | -10M | -54M | -375M | -87M | 83M | 221M | 239M | 251.32M | 286.17M |
Effective Tax Rate % | 238.08% | 0.24% | 2.94% | 40.15% | 8.5% | -64.34% | -56.67% | 143.11% | 67.3% | -31.09% |
Net Income | 2.4B▲ 0% | -4.15B▼ 272.5% | -1.78B▲ 57.0% | -559M▲ 68.6% | -948M▼ 69.6% | -225M▲ 76.3% | -592M▼ 163.1% | -46M▲ 92.2% | 159.75M▲ 447.3% | -1.19B▲ 0% |
Net Margin % | 27.56% | -49.5% | -20.73% | -6.96% | -11.24% | -2.77% | -6.76% | -0.48% | 1.53% | -11.27% |
Net Income Growth % | 199.79% | -272.55% | 57.02% | 68.65% | -69.59% | 76.27% | -163.11% | 92.23% | 447.28% | -2886.81% |
Net Income (Continuing) | 2.4B | -4.14B | -1.78B | -559M | -937M | -212M | -611M | -72M | 122.1M | -1.21B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 95M | 82M | 73M | 70M | 72M | 952M | 940M | 957M | 929.31M | 977M |
EPS (Diluted) | 8.59▲ 0% | -11.86▼ 238.1% | -5.06▲ 57.3% | -1.57▲ 69.0% | -2.61▼ 66.2% | -0.62▲ 76.2% | -1.62▼ 161.3% | -0.13▲ 92.0% | 0.43▲ 430.8% | -3.19▲ 0% |
EPS Growth % | 223.78% | -238.07% | 57.34% | 68.97% | -66.24% | 76.25% | -161.29% | 91.98% | 430.77% | -2758.41% |
EPS (Basic) | 8.63 | -11.86 | -5.06 | -1.57 | -2.61 | -0.62 | -1.62 | -0.13 | 0.43 | - |
Diluted Shares Outstanding | 351.8M | 349.87M | 352.1M | 355M | 358.9M | 362M | 364.9M | 368M | 375M | 372.8M |
Basic Shares Outstanding | 350.2M | 349.87M | 352.1M | 355M | 358.9M | 362M | 365.43M | 368M | 370.9M | 372.8M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BHC Balance Sheet
Bausch Health Companies Inc. (BHC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 4.75B | 723M | 6.97B | 5.34B | 5.61B | 4.25B | 5.6B | 5.77B | 6.15B | 5.98B |
Cash & Short-Term Investments | 720M | 721M | 3.24B | 605M | 582M | 564M | 947M | 1.18B | 1.32B | 1.3B |
Cash Only | 720M | 721M | 3.24B | 605M | 582M | 564M | 947M | 1.18B | 1.32B | 1.3B |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 2.13B | 1.86B | 1.84B | 1.58B | 1.77B | 1.79B | 2B | 2.14B | 2.35B | 2.19B |
Days Sales Outstanding | 89.12 | 81.23 | 78.04 | 71.71 | 76.82 | 80.42 | 83.28 | 81.15 | 82 | 79.23 |
Inventory | 1.05B | 934M | 1.11B | 1.09B | 993M | 1.09B | 1.54B | 1.59B | 1.63B | 1.6B |
Days Inventory Outstanding | 150.13 | 145.01 | 171.94 | 177.55 | 151.4 | 168.3 | 220.23 | 209.26 | 145.31 | 146.16 |
Other Current Assets | 77M | 2M | 10M | 1.22B | 1.54B | 39M | 1.11B | 858M | 850.45M | 887M |
Total Non-Current Assets | 32.75B | 28.28B | 26.89B | 25.86B | 23.59B | 21.44B | 21.75B | 20.75B | 20.17B | 18.52B |
Property, Plant & Equipment | 1.4B | 1.35B | 1.47B | 1.57B | 1.6B | 1.6B | 1.71B | 1.78B | 2.07B | 2.1B |
Fixed Asset Turnover | 6.22x | 6.19x | 5.87x | 5.12x | 5.28x | 5.08x | 5.13x | 5.41x | 5.05x | 5.16x |
Goodwill | 15.59B | 13.14B | 13.13B | 13.04B | 12.46B | 11.55B | 11.18B | 11.09B | 11.25B | 9.81B |
Intangible Assets | 15.21B | 12B | 10.2B | 8.45B | 6.95B | 5.8B | 6.46B | 5.55B | 4.63B | 4.4B |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 111M | 109M | 411M | 664M | 340M | 326M | 307M | 363M | 377.31M | 369M |
Total Assets | 37.5B▲ 0% | 27.45B▼ 26.8% | 33.86B▲ 23.4% | 31.2B▼ 7.9% | 29.2B▼ 6.4% | 25.69B▼ 12.0% | 27.35B▲ 6.5% | 26.52B▼ 3.0% | 26.32B▼ 0.8% | 24.5B▲ 0% |
Asset Turnover | 0.23x | 0.31x | 0.25x | 0.26x | 0.29x | 0.32x | 0.32x | 0.36x | 0.40x | 0.40x |
Asset Growth % | -13.86% | -26.8% | 23.38% | -7.87% | -6.4% | -12.04% | 6.48% | -3.02% | -0.77% | -4.17% |
Total Current Liabilities | 4.27B | 3.84B | 6.25B | 4.91B | 5.2B | 3.94B | 4.3B | 6.75B | 4.17B | 4.53B |
Accounts Payable | 365M | 411M | 503M | 337M | 407M | 521M | 719M | 656M | 598.91M | 593M |
Days Payables Outstanding | 52.29 | 63.81 | 78.13 | 54.69 | 62.05 | 80.44 | 102.55 | 86.07 | 53.52 | 54.92 |
Short-Term Debt | 209M | 228M | 1.23B | 0 | 0 | 432M | 450M | 2.67B | 296.46M | 889M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.21B | 946M | 2.42B | 2.75B | 2.98B | 1.34B | 1.4B | 1.33B | 2.85B | 1.15B |
Current Ratio | 1.11x | 0.19x | 1.12x | 1.09x | 1.08x | 1.08x | 1.30x | 0.86x | 1.47x | 1.32x |
Quick Ratio | 0.87x | -0.06x | 0.94x | 0.86x | 0.89x | 0.80x | 0.94x | 0.62x | 1.08x | 0.97x |
Cash Conversion Cycle | 186.96 | 162.43 | 171.85 | 194.57 | 166.16 | 168.28 | 200.95 | 204.35 | 173.79 | 170.47 |
Total Non-Current Liabilities | 27.29B | 25.84B | 26.48B | 25.68B | 24.04B | 21.48B | 23.13B | 20.09B | 21.77B | 21.05B |
Long-Term Debt | 25.23B | 24.08B | 24.66B | 23.93B | 22.65B | 20.33B | 21.94B | 18.94B | 20.72B | 19.88B |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 165M | 189.65M | 209.65M |
Deferred Tax Liabilities | 1.18B | 885M | 705M | 528M | 529M | 202M | 163M | 128M | 146.73M | 614.59M |
Other Non-Current Liabilities | 870M | 879M | 1.11B | 1.23B | 855M | 949M | 1.03B | 857.49M | 711.7M | 976M |
Total Liabilities | 31.55B | 29.68B | 32.73B | 30.59B | 29.24B | 25.43B | 27.43B | 26.84B | 25.94B | 25.58B |
Total Debt | 25.44B | 24.3B | 25.89B | 23.93B | 22.65B | 20.77B | 22.39B | 21.83B | 21.21B | 20.8B |
Net Debt | 24.72B | 23.58B | 22.65B | 23.32B | 22.07B | 20.2B | 21.44B | 20.65B | 19.88B | 19.5B |
Debt / Equity | 4.28x | 8.63x | 22.79x | 39.55x | - | 79.87x | - | - | 56.36x | -19.22x |
Debt / EBITDA | 8.60x | 55.87x | 13.83x | 9.57x | 11.32x | 11.24x | 10.05x | 7.76x | 6.14x | 5.75x |
Net Debt / EBITDA | 8.35x | 54.22x | 12.10x | 9.32x | 11.02x | 10.93x | 9.63x | 7.34x | 5.76x | 5.39x |
Interest Coverage | 0.30x | 0.30x | 0.83x | 0.86x | 1.20x | 1.01x | 1.22x | 1.35x | 1.35x | 1.43x |
Total Equity | 5.94B▲ 0% | 2.81B▼ 52.6% | 1.14B▼ 59.6% | 605M▼ 46.7% | -34M▼ 105.6% | 260M▲ 864.7% | -82M▼ 131.5% | -322M▼ 292.7% | 376.31M▲ 216.9% | -1.08B▲ 0% |
Equity Growth % | 82.44% | -52.64% | -59.64% | -46.74% | -105.62% | 864.71% | -131.54% | -292.68% | 216.87% | 277.76% |
Book Value per Share | 16.90 | 8.05 | 3.23 | 1.70 | -0.09 | 0.72 | -0.22 | -0.88 | 1.00 | -2.90 |
Total Shareholders' Equity | 5.85B | 2.73B | 1.06B | 535M | -106M | -692M | -1.02B | -1.28B | -552.99M | -2.06B |
Common Stock | 10.09B | 10.12B | 10.17B | 10.23B | 10.32B | 10.39B | 10.42B | 10.49B | 10.5B | 10.54B |
Retained Earnings | -2.73B | -5.66B | -7.45B | -8.01B | -8.96B | -9.19B | -9.78B | -9.82B | -9.65B | -11.09B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.9B | -2.14B | -2.09B | -2.13B | -1.92B | -2.06B | -1.88B | -2.18B | -1.76B | -1.81B |
Minority Interest | 95M | 82M | 73M | 70M | 72M | 952M | 940M | 957M | 929.31M | 977M |
BHC Cash Flow Statement
Bausch Health Companies Inc. (BHC) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 2.29B | 1.5B | 1.5B | 1.11B | 1.43B | -728M | 1.03B | 1.6B | 1.4B | 1.42B |
Operating CF Margin % | 26.25% | 17.91% | 17.45% | 13.84% | 16.91% | -8.96% | 11.78% | 16.59% | 13.4% | - |
Operating CF Growth % | 9.73% | -34.45% | 0% | -25.98% | 28.35% | -151.05% | 241.76% | 54.75% | -12.34% | -31.85% |
Net Income | 2.4B | -4.14B | -1.78B | -559M | -937M | -212M | -611M | -72M | 120M | -1.19B |
Depreciation & Amortization | 2.86B | 2.82B | 2.08B | 1.82B | 1.55B | 1.39B | 1.26B | 1.27B | 1.21B | 1.2B |
Stock-Based Compensation | 87M | 87M | 102M | 105M | 128M | 126M | 132M | 150M | 216M | 141M |
Deferred Taxes | -4.39B | -144M | -230M | -475M | -225M | -176M | 51M | 66M | 80M | 121.77M |
Other Non-Cash Items | 483M | 2.87B | 1.66B | 581M | 1.04B | -1.46B | 778M | 179M | -1.17M | 1.55B |
Working Capital Changes | 844M | 18M | -318M | -366M | -128M | -396M | -582M | 7M | -222.83M | -363.34M |
Change in Receivables | 417M | 216M | 39M | 170M | -229M | -57M | -195M | -216M | -136.35M | -94.72M |
Change in Inventory | 7M | -5M | -209M | -77M | -16M | -198M | -322M | -267M | -12.21M | 3.92M |
Change in Payables | 387M | -568M | -149M | -471M | 121M | -75M | 158M | 357M | -77.33M | -439.12M |
Cash from Investing | 2.89B | -196M | -419M | -261M | 409M | -303M | -2.15B | -454M | -595M | -608.71M |
Capital Expenditures | -336M | -235M | -278M | -302M | -269M | -218M | -215M | -337M | -397M | -392.38M |
CapEx % of Revenue | 3.85% | 2.8% | 3.23% | 3.76% | 3.19% | 2.68% | 2.46% | 3.5% | 3.8% | 3.72% |
Acquisitions | -165M | 5M | -180M | 0 | 0 | -45M | -1.89B | 0 | 0 | -195.27M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 3.39B | 34M | 45M | 37M | 682M | -45M | -39M | -119M | -195M | -18.01M |
Cash from Financing | -4.96B | -1.35B | 1.44B | -2.29B | -1.51B | -474M | 1.48B | -868M | -742M | -692.65M |
Debt Issued (Net) | -4.78B | -1.16B | 1.55B | -2.19B | -1.34B | -1.01B | 1.58B | -799M | -648.15M | -577.53M |
Equity Issued (Net) | 0 | -10M | -40M | 0 | 0 | 675M | 0 | -26M | 0 | -3M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -4M | -10M | -40M | 0 | 0 | 0 | 0 | -26M | 0 | -3M |
Other Financing | -184M | -186M | -71M | -107M | -173M | -139M | -106M | -43M | -93.85M | -112.12M |
Net Change in Cash | 255M▲ 0% | -74M▼ 129.0% | 2.52B▲ 3506.8% | -1.43B▼ 156.6% | 303M▲ 121.2% | -1.53B▼ 604.3% | 371M▲ 124.3% | 239M▼ 35.6% | 124M▼ 48.1% | 153.89M▲ 0% |
Free Cash Flow | 1.95B▲ 0% | 1.27B▼ 35.2% | 1.22B▼ 3.4% | 802M▼ 34.4% | 1.14B▲ 42.5% | -996M▼ 187.1% | 760M▲ 176.3% | 1.26B▲ 65.8% | 1B▼ 20.4% | 989.53M▲ 0% |
FCF Margin % | 22.4% | 15.11% | 14.22% | 9.99% | 13.55% | -12.26% | 8.68% | 13.09% | 9.6% | 9.38% |
FCF Growth % | 8.8% | -35.21% | -3.4% | -34.42% | 42.52% | -187.14% | 176.31% | 65.79% | -20.4% | -18.5% |
FCF per Share | 5.55 | 3.62 | 3.47 | 2.26 | 3.18 | -2.75 | 2.08 | 3.42 | 2.67 | 2.65 |
FCF Conversion (FCF/Net Income) | 0.95x | -0.36x | -0.84x | -1.99x | -1.50x | 3.24x | -1.74x | -34.72x | 8.76x | -0.83x |
Interest Paid | 1.71B | 0 | 0 | 0 | 0 | 1.54B | 1.53B | 1.67B | 0 | 0 |
Taxes Paid | 179M | 0 | 0 | 0 | 0 | 266M | 237M | 61M | 0 | 0 |
BHC Key Ratios
Bausch Health Companies Inc. (BHC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 52.25% | -94.71% | -90.26% | -64.22% | -332.05% | -199.12% | -665.17% | - | 588.24% | 2343.44% |
Return on Invested Capital (ROIC) | 0.24% | -6.27% | -0.61% | 2.13% | 1.47% | 1.6% | 3.45% | 5.56% | 8.22% | 9.2% |
Gross Margin | 70.79% | 71.95% | 72.68% | 71.98% | 71.61% | 70.9% | 70.78% | 71.1% | 60.9% | 61.67% |
Net Margin | 27.56% | -49.5% | -20.73% | -6.96% | -11.24% | -2.77% | -6.76% | -0.48% | 1.53% | -11.27% |
Debt / Equity | 4.28x | 8.63x | 22.79x | 39.55x | - | 79.87x | - | - | 56.36x | -19.22x |
Interest Coverage | 0.30x | 0.30x | 0.83x | 0.86x | 1.20x | 1.01x | 1.22x | 1.35x | 1.35x | 1.43x |
FCF Conversion | 0.95x | -0.36x | -0.84x | -1.99x | -1.50x | 3.24x | -1.74x | -34.72x | 8.76x | -0.83x |
Revenue Growth | -9.82% | -3.94% | 2.64% | -6.67% | 5.07% | -3.68% | 7.79% | 9.91% | 8.53% | 8.52% |
Related:BHC Dividend History·BHC Revenue History·BHC Price History·BHC P/E History·BHC Financial Ratios·BHC Institutional Holders
BHC SEC Filings & Documents
Bausch Health Companies Inc. (BHC) SEC filings — annual & quarterly reports (10-K, 10-Q)
BHC Frequently Asked Questions
Bausch Health Companies Inc. (BHC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bausch Health Companies Inc. (BHC) reported $10.55B in revenue for fiscal year 2025. This represents a 15792% increase from $66.4M in 1996.
Bausch Health Companies Inc. (BHC) grew revenue by 8.5% over the past year. This is steady growth.
Bausch Health Companies Inc. (BHC) reported a net loss of $1.19B for fiscal year 2025.
Dividend & Returns
Bausch Health Companies Inc. (BHC) has a return on equity (ROE) of 588.2%. This is excellent, indicating efficient use of shareholder capital.
Bausch Health Companies Inc. (BHC) generated $989.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.